Niko-Lek Mint (Nicotine)

Nicotine, the active ingredient in Niko-Lek Mint, is a nicotine replacement therapy presented as an oromucosal mint for oromucosal use. It treats nicotine dependence and aids smoking cessation in adult smokers.

GNH USA supplies Niko-Lek Mint as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Niko-Lek Mint, a nicotine replacement therapy, is used to manage nicotine withdrawal in the context of smoking cessation.

- Smoking cessation: helps adult smokers quit by reducing cravings and withdrawal symptoms. - Nicotine dependence: provides controlled nicotine to ease the transition away from cigarettes. - Tobacco use disorder: supports gradual reduction of tobacco intake while maintaining nicotine levels.

Niko-Lek Mint may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Mouth irritation or soreness - Nausea or upset stomach - Dizziness or light‑headedness - Headache - Increased salivation or hiccups - Throat discomfort

Serious or Rare Side Effects: - Elevated blood pressure or hypertension - Irregular heart rhythm (arrhythmia) - Chest pain or palpitations - Severe allergic reaction (rash, swelling, difficulty breathing) - Persistent vomiting - Signs of nicotine toxicity (confusion, seizures).

Before using Niko-Lek Mint, consider the following safety measures.

- Cardiovascular assessment: patients with recent heart attack or uncontrolled hypertension should use with caution. - Pregnancy and lactation: consult a healthcare professional before use, as safety data are limited. - Age restriction: intended for adult smokers; not recommended for individuals under 18 years. - Concomitant nicotine products: avoid using other nicotine replacement therapies simultaneously to prevent excess exposure. - Storage: Store at ambient temperature: keep in the original pack, protect from moisture and direct heat.

Nicotine may interact with other medicines, altering their effects or increasing adverse reactions.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may amplify hypertensive response. - Beta‑blockers: nicotine‑induced tachycardia may be masked, complicating cardiovascular monitoring.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors (e.g., methoxsalen): can reduce nicotine metabolism, increasing plasma levels. - Anticoagulants (e.g., warfarin): nicotine may affect platelet function, requiring INR monitoring. - Alcohol: concurrent use can enhance nicotine dependence and cardiovascular strain.